Solasia Pharma K.K. provided consolidated financial guidance for the fiscal year ending December 31, 2023. For the year, the company expects revenue in the range of ¥1,000 million to ¥1,800 million, operating loss in the range of ¥1,150 million to ¥350 million, loss in the range of ¥1,150 million to ¥350 million, basic loss per share in the range of ¥6.85 to ¥2.08.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28 JPY | 0.00% | +7.69% | -37.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.78% | 32.59M | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-9.42% | 33.03B | |
+55.32% | 24.68B | |
-16.36% | 15.12B | |
-9.19% | 12.81B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023